In 2015, GLA funded a drug discovery program with Dr. Kim Lewis at Northeastern University, leading to the discovery of hygromycin A, an overlooked antibiotic from 1953. Fast forward to 2021, and Dr. Lewis’s lab revealed that hygromycin A is highly effective against Lyme bacteria and can potentially cure early Lyme disease and prevent chronic conditions.
Building upon this discovery, GLA proudly partnered with Dr. Lewis and Flightpath Biosciences, a biotechnology company. GLA Chief Scientific Officer Timothy Sellati, Ph.D., says, “Flightpath Biosciences will usher hygromycin A along the commercialization path, through clinical trials and FDA approval, ultimately reaching physicians.” Remarkably, not only does hygromycin A kill the Lyme bacteria in the test tube and in animal studies but unlike antibiotics such as doxycycline, it is unlikely to harm the ‘good’ bacteria in a patient’s intestines.
Today, GLA is excited to announce that hygromycin A (FP-100) is moving into the clinic in Q1 2024 for human clinical trials. CEO of Flightpath Biosciences, Matt Tindall, emphasizes, “This landmark achievement for Lyme patients could not have been reached without the kind and generous financial support of GLA and its community.”
We eagerly anticipate progress and the road ahead, working together to bring hygromycin A (FP-100) into the hands of physicians.
_________________
**Comment**
While not diminishing the potential importance of this, it’s use in preventing or treating persistent infections was not determined. The subset of patients with chronic debilitating symptoms continues to be ignored.
We now learn that a U.S. government ‘cartel’ bribed large pharmacy chains like Walgreens and CVS with billions of dollars in contracts to promote COVID-19 vaccines and not fill prescriptions for ivermectin.
Go here to learn of all the things ivermectin does, where to get it, and treatment protocols.
“The War on Ivermectin” Isn’t Just Your Favorite Book, Now It’s Also A Documentary
Acclaimed filmmaker Mikki Willis documented the disinformation campaign that discredited ivermectin around the world. Now updated and rebranded, the movie exposes their wicked tactics.
Covid may be fading faster than last week’s sunburn (likely to make way for the “next pandemic”), but the war on ivermectin rages on. And it’s no wonder, as we continue to discover its efficacy against increasing numbers of viral illnesses and now, even cancers. Of course, the more ivermectin threatens these insanely lucrative markets, the more enemies it racks up. (If you thought the Covid market was massive, in the end, cancer may be even bigger – the global chemotherapy market alone is expected to reach $330 Billion by 2029.)
Mikki Willis is a bestselling author, investigative filmmaker, and now, a friend. (He also used to be an old lefty/progressive like me – emphasis on the “used to be.”) In 2020, he released the first installment of his documentary series, Plandemic. The micro-budget documentary was watched and shared by over one billion people world-wide, making it the most seen independent movie in history. Plandemic 2: Indoctornation, set a streaming world-record with 2 million viewers attending the online premiere. Plandemic 3: The Great Awakening, was released in June of 2023 and is being hailed by critics as, “the most important movie of this era.” Note that the Plandemic trilogy can be seen for free at PlandemicSeries.com.
More relevant to my cause is that last year, Mikki released a short but powerful documentary detailing how ivermectin, the now infamous Nobel Prize-winning medication, had been slandered during the COVID pandemic. Well, a lot has happened in the year since, so Mikki has masterfully updated the film and rebranded it The War on Ivermectinto selflessly help support my book with explosive new clips and critical legal developments. (Go to top link for article and “must see” 12 minute documentary)
Another “dog dewormer,” Fenbendazole (Fenben) cured this man of stage four cancer. It appears that there is no significant difference between albendazole and fenbendazole as both are types of benzimidazole or antihelminthic drugs often used against GI parasites, giardia, roundworms, hookworms, whipworms, tapeworm genus Taenia, etc. Albenza and other “de-wormers” are often used in Lyme/MSIDS treatment against worms as ticks transmitparasitic worms.
I’ll never forget something Master Herbalist Stephen Buhner (RIP) stated: (highly paraphrased and I can’t remember where I read it)
A savvy, sophisticated, effective treatment works in tandem and overlaps.
In other words, good treatments often do multiple things simultaneously and symbiotically. I’ve never forgotten those words and would agree 100%.
Allopathic medicine wants to extract individual components so they can make money off of each component. They also can’t stand it when a drug/product does multiple things because they can’t reap enough profits. This is why ivermectin had to be destroyed. They knew it was a wonder drug but kept it from the public, allowing millions to die. Do not trust these scoundrels ever again. Do your homework.
As we predicted, the agency has targeted the next group of homeopathic products for elimination. Action Alert!
The FDA is pressing forward in its plan to win its century long battle to eliminate homeopathic products from the medicine cabinets of Americans—a battle that was started with the Flexner report of 1910. The agency sent warning letters to several manufacturers of homeopathic eye care products in addition to Amazon for selling the products. These letters rely on the change in policy the FDA announced in 2018 that essentially made all homeopathic products illegal. Unless the FDA is held in check, we will continue to lose access to homeopathic medicine bit by bit until there is nothing left. We cannot let that happen.
The FDA indicates in these letters that it is going after eye drops because that route of administration is particularly dangerous from a public health perspective: “these products… in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.” Companies receiving these letters include Boiron, Similasan, Walgreens, and CVS. Some of the letters mention issues with manufacturing and product sterility. Like allopathic drugs, homeopathic products are required to follow good manufacturing practices.
This is in line with the approach outlined in the FDA’s guidance that stipulates certain categories of homeopathic medicines will be targets for enforcement actions. In 2020, the agency went after injectable homeopathic products on similar grounds.
As ever, this has almost nothing to do with safety and everything to do with control. We see this with pharmacy compounding, too, which are medicines that do not need to go through the FDA approval process. The FDA does not like that there are medicines out there that it does not have authority over, so it does everything in its power to eliminate them, using safety as a justification—as if FDA approval was any guarantee of safety! New prescription drugs have a 20 percent chance of causing a serious adverse reaction after being approved; properly prescribed drugs cause 1.9 million hospitalizations a year, and 128,000 people die from drugs prescribed to them.
Meanwhile, Similasan, one of the homeopathic products that generated an FDA warning letter, has a total of five adverse events listed in the FDA’s database. The letter sent to Boiron for its Optique 1 Eye Drops makes no mention of any safety issues whatsoever. The same was true of some of the injectable homeopathic products that were targeted. This comports with other data showing a vanishingly small rate of adverse events from homeopathic medicines.
As Similasan was among the products cited by the FDA for not following good manufacturing practices, the company has voluntarily suspended sale of its eye drops in the US as it resolves the issues raised by the FDA. For those seeking alternative medicines for dry eyes, blepharitis, and related conditions, we like medicines with hyaluronic acid (available, for example, as Hycosan) or carmellose sodium (including Optase).
This all supports the idea that the FDA’s issue is not that these medicines are a threat to consumer safety; they simply haven’t kissed the FDA’s ring, by which we mean paying exorbitant sums to go through the agency’s drug approval process.
Remember:The FDA gets a large part of its funding from drug company user fees, and for this reason sees Big Pharma as its client. Homeopathic medicines, like supplements and other natural products, compete with pharmaceutical drugs, so the FDA uses its enormous power to tilt the scales in favor of the drug companies. And because natural products and homeopathic medicines generally cannot be patent protected like drugs can, they can’t afford FDA approval and so cannot make disease claims. It is one among many ways cronyism is undermining healthcare in this country.
Action Alert! Write to Congress in support of a legislative fix to protect access to homeopathic medicines. Please send your message immediately. (Go to top link to take action against FDA extortion)
Peptides represent an exciting and rapidly developing new frontier in disease treatment and prevention as well as anti-aging, so naturally the FDA is swooping in…to make sure Big Pharma has a monopoly. Action Alert!
Do you want to increase your lifespan by 30 percent? Heal from injuries that conventional medicine has no answers for? Investigations into the use of peptide bioregulators are showing these kinds of promising results, but the FDA is working to make sure patients and doctors cannot access these medicines unless they are approved as drugs. We need a major grassroots response to make sure this doesn’t happen to these natural miracle molecules made from amino acids.
Peptides in peril: What happened?
Simply put, the FDA’s new guidance is prohibiting the compounding of a group of peptides, including many comprised of essential and conditionally-essential amino acids, like BPC-157, epitalon, LL-37, thymosin alpha-1 (Ta1), Kisspeptin-10, and more. The FDA’s justification for “taking action against a compounder or outsourcing facility” for producing these peptides is based on safety concerns. These safety concerns are, in our view, largely spurious, with the FDA generally claiming lack of safety data, the presence of impurities, or suggesting ‘immunogenicity.’ Lack of data certainly doesn’t imply risk, impurities can be eliminated with good manufacturing practice, and immunogenicity simply means the peptide primes or enhances the immune system, a property that could be regarded as beneficial, not harmful.
The FDA hasn’t instigated a permanent ban; it is an interim policy on these compounds, but this is a deeply concerning sign for future access, particularly because the FDA is using the safety risk as its justification to get these products out of compounding. If they’re not safe enough in compounding, how will the FDA respond to these peptides being sold in dietary supplements? Go figure. Currently, not many peptides are available as supplements, and few have yet to be approved as drugs. This means that patients and others who are dependent on these peptides as compounded medicines will lose access to them. Once again, the FDA is standing in the way of patients utilizing cutting edge natural therapies to help them live long, healthy lives.
Background: War on Compounding
This a new step in the FDA’s war on pharmacy compounding, a war that we’ve been drawing public attention to for years. These are specialist pharmacies that create customized medicines for patients with special needs, such as an alternative dosage forms, delivery mechanisms, or preparations that aren’t commercially available. They have, for example, been vital in the supply of bioidentical hormones for women looking for natural alternatives to synthetic hormone replacement therapy.
According to the law, to be eligible to be made at a compounding pharmacy, a medicine must either: 1) be a component of an FDA-approved drug, 2) have a USP monograph, or 3) appear on a list (referred to as the Bulk Drug List) developed through regulation by the FDA.
The agency elicited nominations to the Bulk Drug List and has, for years, been reviewing these nominations to determine which will be added to the List and which will be banned. As the peptides in question do not satisfy conditions 1 or 2 above, they were nominated for inclusion on the Bulk Drug List.
The FDA’s review process has been extremely slow, but the track record is not good, with a number of nominated natural products being banned, such as curcumin, acetyl-L-carnitine, aloe vera, artemisinin, astralagus, and more.
As the FDA goes through its process, it has released an interim policy covering whether substances that have been nominated to the Bulks List can continue to be compounded while the FDA reviews nominations. There are three categories. Substances added to Category 1 can continue to be compounded. Category 2 substances cannot be compounded in the interim due to “safety risks” identified by the FDA (and it’s in this category that the 17 peptides we’re drawing attention to in this article have found themselves listed). Category 3 substances need to be renominated because the FDA did not receive enough information to make an evaluation.
The FDA, in our view, could have — and should have — added these peptides to Category 1 and not disrupted patient access to clinically effective therapies with a strong safety profile. Peptides could theoretically be moved to Category 1, or even better, added to the Bulk List at some point, but the fact that the FDA is citing safety concerns is a clear indication of its intention to move to a ban in compounding and as dietary supplements.
Big Pharma Giveaway
By starting us down the road of a compounded peptide ban, the agency is clearing the market and preparing the way for the drug industry to come in and claim monopolies on crucial peptides used medicinally.
For example, one of the now-banned compounded peptides is thymosin alpha-1, or Ta1, a naturally-occurring peptide in the thymus. The synthetic version of Ta1 is approved as a drug in over 30 countries, though not in the US, to treat chronic hepatitis B and C as well as having an orphan drug indication for cancer treatment. Ta1 has, in fact, far-ranging applications that have yet to be tapped—no wonder there have been dozens of clinical trials looking at Ta1 for the treatment of a variety of diseases. Another of the targeted peptides is BPC-157, which has shown promise in a wide range of central nervous system disorders and other diseases.
We believe the FDA’s overarching goal is to preserve these and other useful, natural peptides for the pharmaceutical industry and shut down competition from compounders.
The main point is, natural peptides—as well as their synthetic versions that are chemically identical—are very clearly both on Big Pharma and the FDA’s radar. That means we must be vigilant in protecting access, lest they become monopoly drugs and harder to access for patients who want to use these peptides to heal themselves, enhance their health, reduce their biological age, or reduce their risk of future disease.
Cutting edge medicine in peril
Losing access to these compounded peptides would be a huge blow for patients and healthcare providers. We will delve further into these issues in future coverage, but research on peptides and their ability to help us heal and extend life is incredibly promising. Peptides are quite simply specific combinations of amino acids which are the building blocks of proteins. Most of the amino acids used in the peptides that have now found their way onto the FDA’s Category 2 list are bioidentical – meaning they are chemically identical to ones found in nature – especially in foods, and in healthy humans and animals.
For example, epitalon, also referred to as Epithalamin, is an extract of the pineal gland. Animal and human research has shown that it can extend life and decrease mortality by, among other things, improving the immune system, stimulating antioxidant defenses, and producing anticarcinogenic effects. Ta1, which we discussed above, is a thymus peptide that has immune-modulating effects. Peptide preparations of the cerebral cortex have been shown to exert neuroprotective effects. The administration of these peptides in animal studies has resulted in 25-40 percent increases in lifespan compared to controls.
We must protect access to these vital compounded peptides.
Action Alert! Write to Congress and the FDA, telling them to retain consumer access to natural peptide medicines! Please send your message immediately. (Go to link to take action)
Higher Incidence of COVID-19 Found Among Consistent Mask-Wearers: Study
Some mask wearers were found to have up to 40 percent higher incidence of infection, contradicting earlier studies and opposing the narrative of mask mandates.
People who wore protective masks were found to be more likely to contract COVID-19 infections than those who didn’t, according to a recent Norwegian study.The peer-reviewed study, published in the journal Epidemiology and Infection on Nov. 13, analyzed mask use among 3,209 individuals from Norway. Researchers followed them for 17 days, and then asked the participants about their use of masks. The team found that there was a higher incidence of testing positive for COVID-19 among people who used masks more frequently.
Among individuals who “never or almost never” wore masks, 8.6 percent tested positive. That rose to 15 percent among participants who “sometimes” used masks, and to 15.1 percent among those who “almost always or always” wore them.
Adjusting for factors such as vaccination status, the study determined that individuals who sometimes or often wore masks had a 33 percent higher incidence of COVID-19, compared to those who never or almost never wore masks. This jumped to 40 percent among people who almost always or always wore them. (See link for article)
_____________
**Comment**
Defying all logic and common sense, mask mandates are returning in many areas despite a Cochrane review analyzing 78 randomized controlled trails that found masks did not show “a clear reduction in respiratory viral infection with the use of medical/surgical masks.”
Florida Surgeon General Joseph Ladapo highlighted the issue of the ineffectiveness of masking policies:
“What do you call re-imposing mask policies that have been proven ineffective or restarting lockdowns that are known to cause harm? You don’t call it sanity,” he said in a post on X. “These terrible policies only work with your cooperation. How about refusing to participate.”
Even the highly bought out CNN is finally questioning masks.
Harry Fisher is a paramedic who works in rural areas, reservations, and suburbs, (all around the US) by his own description, and has been in the health field since 1997. He has not taken any Covid shots, and did not wear masks—his health is good, and he is creating short video testimonials about what he has seen on the battlefield.
The first clip of his that I saw, a few nights ago, told of nine women coming in in one shift,bleeding profusely from what he calls spontaneous abortions, a few months into the vaccine rollout/push for pregnant women.
“I had to get someone to come clean the chairs in the waiting room because the blood was so bad.” Clip here.
Another clip describes the horrific pressures health care workers were under to get injected, even as their loved ones were dropping dead. The staff had to intubate their recently injected nurse manager. (See link for article and video clips)
Fisher says he was banned for “terroristic activity,” when he first started to speak out about the strokes, clots, deaths, and more of what he saw after the COVID gene therapy injections.
But the real story, is the lack of answers about Happy Hypoxia.
Here, Fisher talks about happy or silent hypoxia (also seen in altitude sickness)and the fact that COVID can causedangerously low oxygen levels but that patients don’t suffer breathlessness, and look and feel fine. Their oxygen levels are so low they should be fainting or experiencing organ damage, but they seemingly do fine until eventually they collapse. Hypoxia, on the other hand, is accompanied with a high respiratory rate. Since happy hypoxia doesn’t have this, it is called “the silent killer.” When he first tried to talk about this on social media, he was banned.
Fisher says he began to study what would make a patient’s saturation levels so low yet allow them to function normally. He found that certain parasites (avian haemosporidian parasites that cause malaria) allow birds to fly higher.
In birds, regenerative or haemolytic anaemia leads to increased erythropoiesis that is rapid production of immature red blood cells stimulated by hypoxia and yet showing normal Hct (and Hb or haemoglobin), despite a substantial parasite load (intensity). Source
It must also be mentioned that while funding was suspended to the Wuhan Lab, a secret Chinese-linked Biotech lab was found in California which was home to 20 potentially infectious agents including malaria. Malaria has also been found in the US for the 1st time in 20 years where they state it’s locally acquired. Perhaps these cases were not caused by mosquitoes.
Despite the poor health and fragile medical system of many sub-Saharan African countries, they persisted with a statistically significantly low number of COVID-19 cases. This was attributed to many factors such as the young population age, the warm weather, the lack of proper diagnosis, previous infection with malaria, the use of antimalarial drugs, etc. Additionally, population genetics appears to play a significant role in shaping the COVID-19 dynamics. This is evident as recent genomic screening analyses of the angiotensin-converting enzyme 2 (ACE2) and malaria-associated-variants identified 6 candidate genes that might play a role in malaria and COVID-19 incidence and severity. Moreover, the clinical and pathological resemblances between the two diseases have made considerable confusion in the diagnosis and thereafter curb the disease in Africa. Therefore, possible similarities between the diseases in regards to the clinical, pathological, immunological, and genetical ascription were discussed.
The majority of studies were about COVID-19 co-infected with malaria, followed by strongyloidiasis, amoebiasis, chagas, filariasis, giardiasis, leishmaniasis, lophomoniasis, myiasis, and toxoplasmosis.
COVID-19 conditions and treatment regimensmay cause some parasites re-emergence, relapse, or re-activation.
Madison Area Lyme Support Group 